AWH (Aspira Women's Health) Forward P/S Multiple

Corporate company logo of Aspira Women's Health Inc (AWH)

The competent management of Aspira Women's Health (AWH) focuses on oncology diagnostics, while the moderate stability of cash flows is based on the volume of laboratory contracts. The business's forward P/S reflects revenue expectations, where the 0.30 level captures the current state. Scaling molecular research optimizes costs, gradually unlocking the company's operating leverage.

AWH aspirawh.com: Forward Price to Sales in the range 07/04/2022 - 04/26/2025

Comprehensive metric breakdowns and analytics for Aspira Women's Health Inc. (AWH)

- business market valuation indicators:
Analysis of all company metrics:AWH (aspirawh.com)
Manufactured products of aspirawh.com

Minimizing fundamental risks requires analyzing the ratio of Aspira Women's Health (AWH) market capitalization to its projected revenue, which allows for an assessment of the premium paid for future growth. This calculation reflects market expectations for the monetization of unique ovarian cancer diagnostic tests, while the company's modeled P/S ratio clearly demonstrates the brand value dynamics from the investors' perspective.

Competitor analysis

Forward P/S Multiple A (agilent.com)|Quest Corp (DGX) - Market Cap to Future Revenue Ratio|ILMN - Price-to-Projected Revenue Ratio|EXAS - Forward P/S Multiple|RVTY (Revvity) - Forward Price-to-Revenue Multiple|Bio-Rad - Forward Price to Sales|Price-to-Projected Revenue Ratio anbio.com|Forward P/S Multiple Sotera Health Company|Price-to-Projected Revenue Ratio QuidelOrtho (QDEL)|OPK - Market Cap to Future Revenue Ratio|caredx.com - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Maravai LifeSciences Corp (MRVI)|FLGT: Forward Price-to-Revenue Multiple|Forward Price to Sales LAB (Fluidigm)|Cytek Biosciences Inc (CTKB) - Price-to-Projected Revenue Ratio|OSUR: Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple XGN|MDXH: Forward Price to Sales|Price-to-Projected Revenue Ratio Lucid Diagnostics Inc. (LUCD)|Price-to-Projected Revenue Ratio PRE (Prenetics Global Limited)|Forward P/S Multiple IMDX (Insight Molecular Diagnostics Inc)|Price to Expected Revenue Ratio TRIB (Trinity Biotech Corp)|PRPH - Price-to-Projected Revenue Ratio|Ainos (AIMD) - Forward Price-to-Revenue Multiple|CoDx (CODX) - Price-to-Projected Revenue Ratio|HSCS (Heart Test Labs) - Price-to-Projected Revenue Ratio|BMRA (Biomerica, Inc.) - Forward P/S Multiple|CDIO (Cardio Diagnostics) - Price to Expected Revenue Ratio|Price-to-Projected Revenue Ratio Onconetix Corp (ONCO)|VRAX (Virax Biolabs Group Limited) - Forward Price to Sales|Forward P/S Multiple BJDX (Bluejay Diagnostics Corp)|Accelerate Diagnostics Inc (AXDX) - Market Cap to Future Revenue Ratio|centogene.com - Forward P/S Multiple|ENZ (Enzo Biochem Inc.) - Market Cap to Projected Revenue|Market Cap to Future Revenue Ratio FRES|Market Cap to Future Revenue Ratio GTG Labs (GENE)|ME (23andme.com) - Forward P/S Multiple|Forward P/S Multiple Psychemedics Inc